Stay updated on Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial

Sign up to get notified when there's something new on the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    1%
    Check dated 2025-06-20T12:39:17.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.2 to version 2.16.3.
    Difference
    0.1%
    Check dated 2025-06-13T05:45:23.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-06T03:19:59.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    2%
    Check dated 2025-05-29T21:39:18.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T05:16:14.000Z thumbnail image
  7. Check
    76 days ago
    Change Detected
    Summary
    The page has undergone significant content changes, including the removal of detailed study information regarding Temelimab's efficacy for treating neuropsychiatric symptoms in Post-COVID-19 Syndrome, while adding a new EudraCT number and a revision update.
    Difference
    24%
    Check dated 2025-04-16T14:35:55.000Z thumbnail image

Stay in the know with updates to Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page.